Program
insulin glulisine
Also written as “Insulin Glulisine”, “Insulin glulisine” and “INSULIN GLULISINE”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus, led by 4 companies.
Drug pageInsulin glulisine: every studyAll 65 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 380 open or running | phase 4since Aug 3, 2006 | Sep 20, 2002 | none ahead |
| ikfe-CROits history only | 20 open or running | phase 4since Aug 15, 2011 | Aug 15, 2011 | none ahead |
| Geropharm | 10 open or running | phase 3since Jul 9, 2025 | Jul 9, 2025 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 10 open or running | phase 1since Aug 31, 2009 | Aug 31, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Geropharm only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 9, 2025First study: phase 3 study in Type 1 Diabetes MellitisFirst studyNCT07070752 · 224 enrolled · Russia
TargetBeta
“Insulin receptor agonist”ChEMBL 37, by rule
Other programs on INSR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Insulin Glarginerule | Sanofi | phase 4 | 190 |
| Insulin Aspartrule | Novo Nordisk | phase 4 | 146 |
| insulin degludecrule | Novo Nordisk | phase 4 | 108 |
| Insulinrule | Pfizer | phase 4 | 50 |
| insulin icodecrule | Novo Nordisk | phase 4 | 30 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| LY3938577 | Eli Lilly | phase 2 | 3 |
Studies
The one study Geropharm leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07070752Type 1 Diabetes Mellitis · Russia | 3 | Completed | Nov 28, 2023 | 224 |
How it is read
Names in the registry
- “Insulin Glulisine”, 12 entries
- “Insulin glulisine”, 11 entries
- “insulin glulisine”, 8 entries
- “INSULIN GLULISINE”, 4 entries
- “INSULIN GLULISINE (HMR1964)”, 2 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 21 studies
- Diabetes Mellitus, Type 1, 16 studies
- Diabetes Mellitus, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.